2024-01-02 14:12:00
© Archyde.com.
PRINCETON, NJ – Soligenix, Inc. (NASDAQ: SNGX), a biopharmaceutical company, announces the launch of a new bivalent vaccine that provides 100% protection once morest Sudan Ebola virus (SUDV) and Marburg virus (MARV) in preclinical trials. It was announced that research results proving its efficacy have been published. The study, a collaboration with the University of Hawaii at Manoa (UHM), was published in the journal Vaccine.
This vaccine candidate, which is stable even at high temperatures, addresses a critical need as there are currently no approved SUDV or MARV vaccines or treatments. The existing Zaire Ebola virus (EBOV) vaccine does not protect once morest these viruses. The efficacy of this bivalent formulation was demonstrated in a rigorous non-human primate challenge model.
The development of this heat-stabilized vaccine was supported by a grant from the National Institutes of Health (NIH) and a Small Business Innovation Research Grant. The vaccine’s formulation can be freeze-dried and stored at room temperature, greatly reducing logistical challenges in vaccine distribution.
Filoviruses, including Ebola virus and Marburg virus, are known for their high mortality rates and caused the largest outbreak in West Africa in 2014. These viruses are transmitted through direct contact with bodily fluids of infected people or animals, and effective vaccines and treatments are urgently needed.
This article was created and translated with the assistance of AI and reviewed by an editor. Please see our Terms of Use for more details.
1704206350
#Soligenics #vaccine #shows #promise #deadly #virus #Investing.com
